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Betatrophin is downregulated 
in pregnant women with a history 
of RYGB operation and a high risk 
of postprandial hypoglycaemia
Michael Leutner1,7, Caspar Matzhold2,3,7, Luise Bellach1, Carola Deischinger1, 
Stefan thurner2,3,4,5, Peter Klimek2,3 & Alexandra Kautzky‑Willer1,6*
Betatrophin is a liver and adipose tissue‑derived protein which has recently been linked to glucose 
metabolism. So far, no data exist about the role of betatrophin in pregnant women with a history of 
Roux‑En‑Y gastric bypass (RYGB) operation with a high risk of postprandial hypoglycaemia. In this 
prospective clinical study, an oral glucose tolerance test (OGTT) and an intravenous glucose tolerance 
test (IVGTT) were performed between the 24th and 28th week of pregnancy and 3–6 months post‑
partum in a cohort of obese and normal‑weight pregnant women, as well as in women with a history 
of RYGB operation. In the cohort of pregnant women with RYGB and exaggerated risk of postprandial 
hypoglycaemic events, basal and dynamic betatrophin levels during the OGTT were lower than in the 
obese or normal‑weight pregnant women (basal levels: 13.66 ± 5.88 vs. 19.03 ± 4.15 vs. 15.68 ± 6.48, 
p = 0.016; OGTT 60′: 13.33 ± 5.40 vs. 17.37 ± 3.16 vs. 15.84 ± 4.99, p = 0.030). During the OGTT, basal 
and dynamic betatrophin levels at 60′ were positively associated with glucose levels at 60 min (r = 0.55, 
p = 0.01 and r = 0.45, p = 0.039). This positive association was followed by significant hypoglycaemic 
events in the RYGB group. It was only in the RYGB group that betatrophin was negatively related 
to the disposition index (rho = ‑0.53, p = 0.014). After pregnancy there was a decrease in basal and 
stimulated betatrophin levels during the OGTT in all three patient groups. In comparison to normal‑
weight and obese pregnant women, women with a history of RYGB operation and a high risk of 
postprandial hypoglycaemic events have lower levels of betatrophin. This indicate a mechanistic role 
in order to decrease the risk of postprandial hypoglycaemia in this specific cohort.
In recent years, a novel protein expressed in liver and adipose tissue has been discovered: betatrophin, also 
referred to as  RIFL1,  ANGPTL82 or  lipasin3. Along with modulations of lipid  metabolism1,2,4, a positive correla-
tion of betatrophin with postprandial glucose levels has been established in  humans5 as well as a positive correla-
tion with insulin  resistance6 and HbA1c  levels7. A connection to diabetes mellitus has also been  established3,8, 
attributing a predictive value for new-onset type 2 diabetes mellitus to  betatrophin9. Thus also during pregnancy 
and especially in women with gestational diabetes mellitus (GDM), elevated levels of betatrophin have been 
reported earlier than in healthy  controls10,11. Additionally, an association of betatrophin levels with RYGB opera-
tion has been  observed12. In their study, Shankar et al. investigated obese patients with a BMI over 35 kg/m2 and 
type 2 diabetes mellitus undergoing RYGB surgery and could show that just 2 weeks after surgery, betatrophin 
levels had dropped significantly, accompanied by improved levels of parameters of glucose metabolism such as 
plasma glucose, insulin and C-peptide12. Further, bariatric surgery has been shown to have a diabetes remission 
rate of about 80%13. However, the exact pathophysiological mechanisms behind the significant improvement 
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in glucose metabolism and especially the increased risk of postprandial hypoglycaemia in this specific cohort 
are not entirely known to date. We have recently shown that glucagon-like peptide 1 (GLP-1) is significantly 
involved in the regulation of postprandial glucose metabolism, and therefore especially in the increased risk of 
postprandial  hypoglycaemia14. However, despite numerous research groups investigating the metabolic implica-
tions of an RYGB  operation12–17, data on betatrophin in certain patient subgroups remain scarce. The aim of the 
present study was to investigate the role of betatrophin on glucose metabolism in the specific cohort of pregnant 
women with a history of RYGB operation and high risk of postprandial hypoglycaemia.
Methods
A detailed description of the methods has been published  previously14,18,19.
Study design. The study at hand is a prospective clinical study evaluating glucose metabolism in pregnant 
women with a history of RYGB operation, obese (OB) pregnant women, and normal-weight (NW) pregnant 
women at the Medical University of Vienna. The study protocol has been approved by the Ethics Committee of 
the Medical University of Vienna and all experiments have been carried out in accordance with the declaration 
of Helsinki. Written informed consent was obtained from all study participants.
Study participants. In this analysis, 25 females with a history of RYGB surgery, 19 OB females with a 
body mass index (BMI) of ≥ 35 kg/m2 before pregnancy, and 19 NW females with a BMI of < 25 kg/m2 before 
pregnancy were included. The exclusion criteria were bypass surgery other than laparoscopic RYGB, infectious 
diseases, liver disease or renal disease. The median time span between RYGB and entry to the study was 3.3 years 
(2.3–5.7).
Tests and procedures. Oral glucose tolerance test (OGTT). Between the 24th and 28th week of gestation 
and 3–6 months after pregnancy, a 3 h 75 g OGTT was performed in the morning after a fasting period of at 
least 8 h. Blood was drawn at 0, 30, 60, 90, 120, 150 and 180 min for the measurement of parameters of glucose 
metabolism and betatrophin. Hypoglycaemia was defined as blood glucose levels under 54 mg/dl.
Intravenous glucose tolerance test (IVGTT). The IVGTT was performed within 1–2 weeks of the OGTT. At time 
point 0, 0.3 g/kg of glucose were infused. 20 min after the beginning of the test, a dose of 0.05 IU/kg body weight 
of insulin was infused. Until 60 min after the start of the IVGTT the plasma concentrations of glucose, insulin 
and C-peptide were assessed.
Assays. Betatrophin was analyzed in EDTA plasma samples using the Human Betatrophin Elisa kit from 
BioVendor (Brno, Czech Republic) according to the manufacturer’s instructions.
Calculations and statistical analysis. For the calculation of the area under the curve (AUC) for betat-
rophin the trapezoidal method was used. The total body insulin sensitivity (ISI(comp)) and beta cell function 
(insulinogenic index) were calculated with the data retrieved from the OGTT. Furthermore, a HOMA-IR index 
to assess hepatic insulin resistance and a Matsuda index for insulin sensitivity were calculated. The disposition 
index, a product of the insulinogenic index and ISI(comp), was used to evaluate pancreatic beta cell function in 
insulin resistance. On the basis of the IVGTT, insulin sensitivity indices, a sensitivity index (SI), and a calculated 
sensitivity index (CSI) were calculated.
In the statistical analysis, means and standard deviations were used for continuous variables, counts and 
percentages for categorical variables. Distribution was tested for normality using the Shapiro–Wilk test. Non-
normally distributed data were logarithmically transformed. An ANOVA (analysis of variance) was carried out 
to evaluate the differences between the three study groups. Differences in glucose levels in each group during and 
after pregnancy were analysed using a paired t-test. For linear dependencies, the Pearson correlation coefficient 
was used. A p-value of < 0.05 was considered statistically significant.
Results
The detailed baseline characteristics of the study population have been published  previously14,18,19. In short, 
pregnant women with a history of RYGB operation are more insulin-sensitive and are characterized by major 
alterations in glucose metabolism, including a high risk of postprandial hypoglycaemic events, when compared 
to obese and normal-weight pregnant women.
As presented in Table 1, pregnant women with a history of RYGB operation show significantly lower basal 
(RYGB: 13.66 ± 5.88 vs. obesity: 19.03 ± 4.15 vs. controls: 15.68 ± 6.48; p = 0.016) and dynamic betatrophin levels 
during the OGTT (see Table 1 and Fig. 1). In particular, the RYGB group showed significantly lower basal and 
dynamic betatrophin levels than the obesity group (OGTT 0′: p = 0.016, OGTT 60′: p = 0.030). Figure 2 presents 
the dynamic changes of glucose values during the OGTT in the three groups, highlighting an increased risk of 
postprandial hypoglycaemic events in the RYGB group.
Relationship between betatrophin levels and parameters and indices of glucose metabolism 
(Table 2, 3). Table 2 shows that a relationship between betatrophin and parameters and indices of glucose 
metabolism could not be observed either in the control group or in the obese pregnant women. Only in the 
RYGB group was there a significant negative correlation between basal betatrophin levels and the area under 
the curve (AUC) during the OGTT with beta cell function in insulin resistance, measured using the disposition 
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index (see Tables 2, 3). Additionally, basal betatrophin and betatrophin levels at 60 min during the OGTT were 
positively related to glucose levels at 60 min during the OGTT in pregnant women with RYGB (see Fig. 3, 4). 
This relationship was closely followed by a significant drop in glucose levels at 90 min during the OGTT (see 
Fig. 2).
Table 1.  Basal and dynamic betatrophin levels during the OGTT in pregnant women. a Group comparison 
using ANOVA. b Significant vs. obesity.
Variable Controls Bypass Obesity p-valuea
Age (years) 31.11 ± 5.93 31.96 ± 6.97 32.05 ± 4.94 0.867
Betatrophin 0′ 15.68 ± 6.48 13.66 ± 5.88b 19.03 ± 4.15 0.016
Betatrophin 60′ 15.84 ± 4.99 13.33 ± 5.40b 17.37 ± 3.16 0.030
Betatrophin 120′ 18.58 ± 5.67 18.58 ± 8.94 19.65 ± 4.43 0.858












































Figure 2.  Dynamic changes in glucose levels during the OGTT (during pregnancy).
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Table 2.  Relationship between basal betatrophin and parameters and indices of glucose metabolism during 
pregnancy (significant relationships highlighted in boldface). a Pearson’s correlation coefficient. b p-value against 
null hypothesis that Pearson’s correlation coefficient is zero.
Variable
Controls Bypass Obesity
N ra pb N ra pb N ra pb
HbA1c 18 0.31 0.214 13 0.03 0.928 16 − 0.06 0.812
Matsuda Index 19 0.00 0.996 21 − 0.31 0.165 16 − 0.23 0.389
HOMA-IR 19 0.11 0.656 21 0.21 0.356 16 0.17 0.522
Insulinogenic Index 18 − 0.10 0.703 21 − 0.24 0.300 16 − 0.20 0.448
Disposition Index 18 − 0.11 0.656 21 − 0.53 0.014 16 − 0.32 0.230
SI_IVGTT 19 0.21 0.391 20 − 0.11 0.636 17 − 0.24 0.356
DI_IVGTT 19 − 0.01 0.964 20 0.06 0.798 17 − 0.24 0.348
CSI 19 0.25 0.310 20 − 0.10 0.672 17 − 0.26 0.308
Table 3.  Relationship between the AUC of betatrophin (0–120′) during the OGTT and parameters and 
indices of glucose metabolism during pregnancy (significant relationships highlighted in boldface). a Pearson’s 
correlation coefficient. b p-value against null hypothesis that Pearson’s correlation coefficient is zero.
Variable
Controls Bypass Obesity
N ra pb N ra pb N ra pb
HbA1c 17 0.39 0.121 13 0.11 0.721 16 − 0.04 0.881
Matsuda Index 18 − 0.26 0.294 21 − 0.27 0.232 16 − 0.32 0.226
HOMA-IR 18 0.44 0.066 21 0.19 0.400 16 0.20 0.454
Insulinogenic Index 17 0.01 0.965 21 − 0.24 0.303 16 − 0.13 0.635
Disposition Index 17 − 0.31 0.231 21 − 0.49 0.024 16 − 0.26 0.34
SI_IVGTT 18 0.07 0.787 20 − 0.08 0.729 17 − 0.32 0.213
DI_IVGTT 18 − 0.10 0.691 20 0.08 0.743 17 − 0.33 0.190
CSI 18 0.09 0.716 20 − 0.05 0.839 17 − 0.33 0.190
Figure 3.  Relationship between basal betatrophin and dynamic glucose levels at 60 min during the OGTT in 
pregnant women with RYGB.
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Post‑partum. As shown in Fig. 5, the dynamic levels of betatrophin decreased significantly in all three study 
groups after pregnancy, yet the most prominent difference can be observed in the control group, which also 
showed a significant change in basal betatrophin levels after pregnancy.
Figure 4.  Relationship between dynamic betatrophin and dynamic glucose levels at 60 min during the OGTT 
in pregnant women with RYGB.
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Figure 5.  Comparison of betatrophin levels during pregnancy and post partum in the (a) control, (b) bypass 
and (c) obesity groups (*p < 0.05, **p < 0.01, ***p < 0.001).
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Discussion
To the best of our knowledge, we were able to show for the first time that pregnant women with a history of RYGB 
surgery have significantly lower basal and dynamic betatrophin levels when compared to obese and normal-
weight pregnant women—indicating a possible downregulation to prevent aggravation of postprandial hypogly-
caemic events. Interestingly, a positive relationship between betatrophin levels at 60′ with dynamic glucose levels 
at 60′ during the OGTT could be observed. This positive relationship was closely followed by a significant drop 
in the glucose values in RYGB patients. Further, we could only find a negative correlation between betatrophin 
and the disposition index, linking betatrophin to beta cell function in insulin resistance, in the RYGB group. 
After pregnancy a significant drop in betatrophin levels could be observed in all groups.
In 2012, betatrophin was newly characterized as a triglyceride level-modulating protein mainly expressed in 
the liver and adipose tissue, also known as  ANGPTL82 or  lipasin3,20. Espes et al. were among the first research 
groups to detect a positive correlation between betatrophin and diabetes mellitus, arguing that betatrophin 
secretion is induced by insulin  resistance7,21. The correlation between betatrophin and diabetes mellitus is backed 
by several  sources9, including a positive association with impaired glucose tolerance (IGT)22, fasting  glucose23, 
insulin  resistance6,24,25 and 2 h-postprandial plasma glucose  levels5. Previously, we have shown that pregnant 
women with a history of RYGB operation are more insulin-sensitive and have an exaggerated risk of postprandial 
hypoglycaemic events when compared to controls. Therefore, GLP-1 was mainly involved in the regulation of 
postprandial glucose metabolism, and was the main driver of the increased risk of postprandial hypoglycaemic 
events in pregnant RYGB  patients14. However, the exact pathophysiological mechanisms of the increased risk 
of postprandial hypoglycaemic events are presently not entirely known and earlier studies hypothesized that 
multiple mechanisms could be related to the dramatic, postoperative changes in glucose metabolism. Interest-
ingly, we could find lower basal and dynamic plasma levels of betatrophin in pregnant women with RYGB when 
compared to controls in the present study. So in the context of earlier studies which hypothesized that betatrophin 
could have beta cell proliferating effects, the lower basal levels and the downregulation of betatrophin during the 
OGTT in the specific cohort of pregnant women with a history of RYGB operation in the present study could 
be a consequence of negative feedback in order to prevent aggravation of postprandial hypoglycaemic events 
in this specific cohort, which were present anyway. Interestingly, we could find a positive association between 
betatrophin and glucose levels at 60 min during the OGTT, indicating that betatrophin is also secreted in a 
compensatory manner in pregnant RYGB patients, albeit in lower levels when compared to controls. This posi-
tive relationship was closely followed by a significant drop in glucose levels, resulting in a dramatic increase in 
hypoglycaemic events in pregnant RYGB patients. Our results showed that there are quick dynamic changes of 
betatrophin concentrations during several time-points of the OGTT. However, studies have yet to investigate the 
exact pathophysiological mechanisms behind the dynamic changes of betatrophin and its release after glucose 
load and the relationship with the regulation of postprandial glucose metabolism, including increased risk of 
postprandial hypoglycaemia in pregnant women with a history of RYGB. Hence a possible physiological down-
regulation of betatrophin in order to prevent a larger drop in glucose levels must be mentioned here. Potential 
negative feedback between betatrophin and insulin resistance has been discussed earlier in a study by Espes et al., 
who compared betatrophin concentrations in type 1 diabetic patients and  controls21. Accordingly, a mouse model 
and cell culture study ascribed betatrophin a regulatory role in the insulin pathway under prevailing insulin 
 resistance26. In the present study, we also found a negative correlation between betatrophin and the disposition 
index in RYGB patients, which presents the beta cell function in insulin  resistance27,28. The lower levels of betat-
rophin in the RYGB group could also indicate a physiological reflex downregulation in order to prevent further 
increasing the risk of postprandial hypoglycaemic events by improving beta cell proliferation, a mechanism which 
has been shown in earlier studies. In the present study, obese pregnant women were characterized by having the 
highest levels of betatrophin. This is an interesting aspect, as it is known that obesity in particular is closely related 
to impaired insulin  sensitivity29, an effect also physiologically prevalent in  pregnancy30. It has long been known 
that different underlying metabolic states occur during pregnancy, mainly effected by physiologically increased 
insulin resistance during gestation in order to ensure sufficient glucose and free fatty acid supply to the fetus. This 
physiologic insulin resistance is induced by increasing levels of the human placental growth hormone (hPGH). 
Besides, the peroxisome proliferator-activated receptor γ (PPARγ) activity is also suppressed, leading to further 
insulin  resistance31. Interestingly, betatrophin has recently been linked to hepatic coexpression of insulin-like 
growth factor-binding protein 1 (IGFBP-1), a protein prolonging the halftime of IGF-1 and IGF-2 and thereby 
involved in improving glucose regulation and insulin sensitivity. A slightly weaker coexpression of peroxisome 
proliferator-activated receptor γ coactivator 1-α (PPARG-C1A), a coactivator of PPARγ has also been  shown32. 
Combining the input of these two papers, a connection to the physiologic hyperglycemic state during pregnancy 
and the coexpression of betatrophin with IGFBP-1 and PPARG-1CA seems plausible. This can also be seen in the 
present study as the betatrophin concentrations drop postpartum, especially in the obese- and normal weight 
cohorts. The question remains whether the increased betatrophin levels are, in part, responsible for the body’s 
response to counteract the reduced insulin sensitivity. A recent study supports this theory by revealing a clear 
increase in betatrophin expression in response to high insulin levels in cell culture, in a mouse model as well as 
in T2DM patients receiving insulin  treatment33 which can be linked to the Akt  pathway33,34. Interestingly, this 
theory has also been confirmed by Wang et al., who showed a clear decline in betatrophin concentrations after 
metformin  treatment24. As the RYGB cohort in the present study shows the lowest betatrophin levels despite 
high postprandial insulin levels, other factors need to be taken into consideration. Liu et al.34 did not investigate 
the influence of rapid and pronounced changes in insulin levels, as this is the case in gastric bypass-operated 
patients in the present study. Also, as betatrophin is an adipose tissue-derived protein, the decrease in visceral 
adipose tissue after an RYGB operation might also partially explain the lower betatrophin levels in the RYGB 
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cohort. Consistent with this theory, for example, we have recently shown that pregnant RYGB patients have lower 
levels of liver fat when compared to obese  controls14.
Our study has limitations which have to be reported. First, the number of participating patients in the three 
groups was low. However, this was a prospective clinical study and the number of participants is comparable to 
earlier studies. Another limitation is that especially after pregnancy the drop-out rate was high and therefore 
the changes in betatrophin levels post-partum are limited to a restricted number of patients. Additionally, the 
conclusions of the present study are based on correlations and not on causative relationships.
To the best of our knowledge, this is the first study to investigate the changes in betatrophin in pregnant 
RYGB-operated women; there is no reference to similar results to date. Further research ought to be conducted on 
this subject in order to precisely make assessments and predictions for the possible implications of these findings. 
Nevertheless, our results show that betatrophin is downregulated in pregnant women with a history of RYGB 
operation and that there is a negative association with the disposition index. It is possible that downregulation 
of basal and dynamic betatrophin levels in RYGB-operated pregnant women is a consequence of the exaggerated 
risk of postprandial hypoglycaemic events.
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